CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 12 enrolled
Drug / intervention
Pembrolizumabdrug
Likely dose
Pembrolizumab 200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02650999
NCT02650999Phase 2Completed
CompareCT.gov

Phase I/II Study of Pembrolizumab in Patients Failing to Respond to or Relapsing After Anti-CD19 Chimeric Antigen Receptor Modified T Cell Therapy for Relapsed or Refractory CD19+ Lymphomas

Abramson Cancer Center at Penn Medicine·interventional·Posted Jan 8, 2016·Updated Jul 22, 2021

In Brief

A Phase 2 clinical trial evaluating Pembrolizumab for CD19+ Diffuse Large B-cell Lymphomas and 2 related conditions. Completed, enrolled 12 participants across 1 site.

Detailed Summary

Single center, phase I/II trial of pembrolizumab after CTL019 for CD19+ lymphomas. Patients will have CD19+ diffuse large B-cell, follicular, or mantle cell lymphomas relapsed/refractory after CTL019. 12 total patients will be enrolled. Safety of pembrolizumab (primary endpoint) will be determined using a Bayesian monitoring rule for treatment-related adverse events causing drug discontinuation. Secondary efficacy endpoints include overall response rate and progression-free survival.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCD19+ Diffuse Large B-cell Lymphomas, Follicular Lymphomas, Mantle Cell Lymphomas
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJan 8, 2016
Enrollment StartJan 1, 2016
Primary CompletionFeb 25, 2019
Study CompletionJun 12, 2020
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 10.5 years ago

Interventions

Pembrolizumabdrug

200mg intravenously (IV)